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Prognostic value of combined use of biomarkers of
inflammation, endothelial dysfunction, and myocardiopathy in
patients with ESRD.
Background. Cardiovascular risk stratification is important
in the clinical management of patients with end-stage renal dis-
eases (ESRD) and biomarkers are increasingly used in these
patients.
Methods. In a cohort of 246 dialysis patients without heart
failure at baseline we tested the combined prognostic power
of three well-established biomarkers: brain natriuretic peptide
(BNP), C-reactive protein (CRP), and asymmetric dimethyl
arginine (ADMA). The independent prognostic value of in-
dividual and combined biomarkers was estimated in separate
Cox models, including standard risk factors in dialysis patients
and comorbidities.
Results. When the prediction power of the three biomark-
ers was evaluated individually, BNP, ADMA, and CRP added
significant predictive value (P ≤ 0.01) to all-cause and cardio-
vascular mortality models and the explanatory gain attributable
to these biomarkers were of similar degree (ranging from 3.3%
to 5.7%). When the biomarkers were evaluated jointly, a score
based on the BNP-CRP combination, increased by 9.9% (all-
cause) and by 10.5% (cardiovascular) the explained mortality
variance of standard Cox models and such gain in power was
similar to that achieved by the CRP-ADMA combination (all-
cause death 9.0% and cardiovascular death 8.4%). Of note, the
explanatory gain derived by the simultaneous use of the three
biomarkers was very similar (all-cause death 11.6% and car-
diovascular death 10.5%) to that achieved by the use of two
biomarkers.
Conclusion. These findings indicate a potential role for
CRP, BNP, and ADMA to be incorporated into diagnostic
and therapeutic strategies aimed at detection and treatment of
atherosclerotic complications and at preventing heart failure in
the dialysis population.
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Cardiovascular complications are the major cause of
death in patients with end-stage renal disease (ESRD),
accounting for approximately one half of all deaths and
the mortality risk attributable to coronary heart disease
in these patients is about 100 times higher than that in the
general population [1]. Even though cardiovascular risk
in patients with chronic kidney diseases now constitutes a
major concern in the nephrology community, ESRD pa-
tients are treated much less intensively than needed [2].
Because of the daunting burden of cardiovascular disease
and the still insufficient emphasis on appropriate treat-
ment, cardiovascular risk stratification is a fundamental
issue in strategies aimed at bettering clinical management
of ESRD patients.
Inflammation, a critical element to the pathogenesis of
atherosclerosis, is a pervasive phenomenon in ESRD and
raised serum C-reactive protein (CRP), a reliable marker
of this process, is demonstrable in up to 70% of patients
on chronic dialysis [3–5]. Furthermore plasma B-type
natriuretic peptide (BNP), a cardiac hormone reflecting
left ventricular mass and function, is frankly elevated in
about 80% of these patients [6, 7]. Likewise, asymmetric
dimethyl arginine (ADMA), an endogenous inhibitor of
nitric oxide synthase (NOS) with potent vasoconstrictive
and proatherogenic effects, is abnormally high in about
60% of the dialysis population [8, 9]. Observations as-
sociating the plasma concentration of these markers to
cardiovascular damage [7, 10] are germane to prospec-
tive studies showing that elevated CRP [3–5], BNP [10],
and ADMA [9] predict increased all-cause and cardio-
vascular death. Notwithstanding the association of each
of these biomarkers with atherosclerotic disease and car-
diomyopathy is fairly well established, the usefulness of
their combined use has been scarcely investigated. The is-
sue is relevant because a study examining the joint use of
CRP and troponin T has convincingly demonstrated that
high troponin T identifies inflamed patients at higher risk
for cardiac death [11].
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In the Cardiovascular Risk Extended Evaluation in
Dialysis (CREED) study, a prospective cohort study in
dialysis patients without heart failure at baseline, we mea-
sured CRP, BNP, and ADMA and reported their prognos-
tic value for all-cause death and cardiovascular events as
well as their relationship with structural surrogate mark-
ers of cardiovascular damage such as left ventricular hy-
pertrophy (LVH) and carotid intima thickness. In the
present study we tested the hypothesis that the combined
measurement of these biomarkers may have a comple-
mentary role for the prognosis of dialysis patients. To this
end we have performed new analyses to estimate the vari-
ance in all-cause and cardiovascular mortality explained
by traditional and nontraditional risk factors and the ad-
ditional explanatory power attributable to biomarkers
used individually and combined.
METHODS
Protocol
The protocol was in conformity to the ethical guidelines
of our institutions and informed consent was obtained
from each participant.
Study cohort
Two hundred and forty six patients with ESRD (138
males and 108 females) who had been on regular dialysis
treatment [196 on hemodialysis and 50 on chronic ambu-
latory peritoneal dialysis (CAPD)] for at least 6 months,
with left ventricular ejection fraction >35% and without
history of clinical evidence of circulatory congestion [12],
were eligible for the study. No patient had inter-current
acute coronary syndromes at the time of the study.
One hundred and seventeen patients had had at least
one cardiovascular event. In particular, 62 patients had
had one cardiovascular event (myocardial infarction in
eight cases, ECG-documented anginal episodes in 28
cases, peripheral artery diseases in 11 cases, arrhythmia
in 10 cases, transient ischemic attacks in four cases, and
stroke in one case) and the remaining 55 patients had
had two or three (N = 46) or more than three (N = 9)
cardiovascular complications.
The main demographic, somatometric, clinical, and
biochemical characteristics of patients included in the
study are detailed in Table 1. Patients represented about
the 70% of the dialysis population of two urban areas.
The remaining 30% of patients were excluded because
of the presence of circulatory congestion or major infec-
tions (20%) or because they were hospitalized for inter-
current illnesses or for logistic reasons/unwillingness to
participate in the study (10%). The prevalence of dia-
betes mellitus in this cohort was 15% (i.e., 37 patients out
of 246).
Table 1. Demographic, anthropometric, clinical, and biochemical
data of the study population
Age years 60.2 ± 15.3
Duration of regular dialysis treatment months 43(18–99)
Body mass index kg/m2 24.9 ± 4.4
Number of males (%) 138 (56%)
Number of diabetics (%) 37 (15%)
Number of smokers (%) 104 (42%)
Number on antihypertensive therapy (%) 109 (44%)
Systolic pressure mm Hg 133.9 ± 22.4
Diastolic pressure mm Hg 75.3 ± 12.3
Heart rate beats/min 80.5 ± 12.0
Hemoglobin g/L 106.4 ± 19.0
Albumin g/L 40.1 ± 5.6
Cholesterol mmol/L 5.34 ± 1.41
Calcium ∗ phosphate mmol2/L2 4.44 ± 1.17
Homocysteine lmol/L 27.0 (19.6–40.2)
Brain natriuretic peptide pmol/L 24.4 (10.4–48.2)
Asymmetric dimethyl arginin lmol/L 3.06 (1.77–4.33)
C-reactive protein mg/L 7.4 (3.4–16.4)
Data are reported as mean ± SD, median and interquartile range or as percent
frequency, as appropriate.
Hemodialysis patients were being treated three times
a week with standard bicarbonate dialysis (sodium 138
mmol/L, HCO3 35 mmol/L, potassium 1.5 mmol/L, cal-
cium 1.25 mmol/L, and magnesium 0.75 mmol/L) by
cuprophan or semisynthetic membranes (dialysis filters
surface area 1.1 to 1.7 m2). Dry weight was targeted
in each case to achieve a normotensive edema-free
state. The average urea Kt/V in these patients [13] was
1.22 ± 0.27. Patients on CAPD were all on four ex-
changes/day schedule with standard dialysis bags. The av-
erage weekly Kt/V in these patients [14] was 1.66 ± 0.32.
One-hundred and four patients were habitual smokers
(21 ± 17 cigarettes/day). One-hundred and thirty patients
were on treatment with erythropoietin. One-hundred
and nine patients were on antihypertensive treatment
[76 on monotherapy with angiotensin-converting enzyme
(ACE) inhibitors, angiotensin II type 1 (AT1) antago-
nists, calcium channel blockers, alpha and beta blockers,
and 33 on double or triple therapy with various combina-
tions of these drugs].
Follow-up study
After the initial assessment patients were followed-
up for an average time of 34 ± 16 months (range
0.8 to 52.0 months). During the follow-up period fa-
tal cardiovascular events (myocardial and mesenteric
infarction, heart failure, ECG-documented arrhythmia,
pulmonary embolism, and stroke) and death were accu-
rately recorded. Each death was reviewed and assigned
an underlying cause by a panel of five physicians. As a
part of the review process, all available medical infor-
mation about each death was collected. This information
always included study and hospitalization records. In the
case of an out-of-hospital death family members were
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interviewed by telephone to better ascertain the circum-
stances surrounding death.
Laboratory measurements
To minimize the effect of cyclic changes in extracel-
lular volume all studies in hemodialysis patients were
performed between 8.00 a.m. and 10.00 p.m. midweek,
during the dialysis interval. Sampling was performed at
empty abdomen in CAPD patients. After 20 to 30 min-
utes of quiet resting in semirecumbent position samples
were taken into chilled ethylenediaminetetraacetic acid
(EDTA) vacutainers, placed immediately on ice, cen-
trifuged within 30 minutes at −4◦C, and the plasma stored
at−80◦C before assay. Serum lipids, albumin, calcium and
phosphate, and hemoglobin measurements were made
by standard methods in the routine clinical laboratory.
Methods of measurements of BNP [10], CRP [15], and
ADMA [9] were detailed in previous papers.
Cardiovascular comorbidity score
This score was calculated on the basis of the pres-
ence/absence of background cardiovascular complica-
tions (previous myocardial infarction, stroke, transient
ischemic attack, ECG-documented arrhythmia, anginal
episodes, and peripheral artery disease). Patients were
classified as having 0, 1, 2, or 3 and more than 3 previous
cardiovascular complications.
Statistical analysis
Data are reported as mean SD, median and interquar-
tile range or as percent frequency, as appropriate. To con-
struct multivariate Cox models, we considered a series of
traditional risk factors (age, gender, smoking, diabetes,
serum cholesterol, systolic pressure, and antihyperten-
sive therapy) and factors peculiar to ESRD [treatment
modality (hemodialysis/CAPD), duration of regular dial-
ysis treatment, hemoglobin, serum albumin, and serum
calcium and phosphate] and plasma total homocysteine.
In a first step we identified covariates that were associated
to all-cause and cardiovascular mortality with P < 0.10 at
univariate Cox regression analysis. These variables were
then jointly included into multivariate Cox models (“ba-
sic models” both for all-cause and cardiovascular death).
We then tested by the −2 log likelihood statistic [16]
whether the sequential addition of the comorbidity score
and of the three biomarkers (BNP, ADMA, and CRP con-
sidered individually and in various combinations) added
significant prognostic information to basic models. Fur-
thermore, to directly compare the relative risk associated
with high BNP, ADMA, and CRP, we categorized these
variables as tertiles and calculated their associated rela-
tive risks. The variance in incident all-cause and cardio-
vascular death explained by covariates in Cox models was
estimated according to Hosmer and Lemeshow [17].
Hazard ratios (HR) and their 95% confidence inter-
vals (CI) were calculated with the use of the estimated
regression coefficients and their standard errors in the
Cox regression analysis. All calculations were done using
a standard statistical package (SPSS for Windows version
9.0.1, March 11, 1999) (SPSS, Chicago, IL, USA).
RESULTS
The main demographic, somatometric, clinical, and
biochemical data of the study population are reported
in Table 1. Plasma BNP, plasma ADMA, and serum CRP
were above the upper limits of the normal range in the
majority of dialysis patients (i.e., 80%, 65%, and 54%,
respectively).
Basic models of all-cause and cardiovascular mortality
During the follow-up period 97 patients died, 59 of
them (i.e., 61% of total deaths) of cardiovascular causes.
On univariate Cox regression analysis age, gender, smok-
ing, diabetes, albumin, and treatment modality were all
significantly associated to death and the multivariate Cox
model based on these variables explained 37.2% of the
variance in all-cause mortality (Fig. 1, upper panel). On
the other hand age, gender, smoking, and diabetes were
predictors of cardiovascular death and the corresponding
multivariate Cox model explained 23.6% in cardiovascu-
lar mortality variance (Fig. 1, lower panel).
Prognostic impact of the cardiovascular comorbidity
score
As expected, the incident risk of all-cause and cardio-
vascular mortality was strongly related with the number
of previous cardiovascular complications (comorbidity
score). Indeed (Table 2), the risk for all-cause and car-
diovascular death increased in parallel with the number
of previous cardiovascular complications so that patients
with a comorbidity score >3 were those with the highest
risk of death. When the comorbidity score was added
to the basic models, the explained mortality variance
reached 45.4% for all-cause death and 36.4% for car-
diovascular death and the corresponding gains in pre-
dictive value were 8.2% and 12.8%, respectively (both
P < 0.001) (Fig. 1).
Prognostic impact of high BNP, ADMA, and CRP
The additional independent prognostic value of plasma
BNP, ADMA, and CRP was tested in separate Cox mod-
els (one model for each biomarker both for all-cause
and cardiovascular death). These models included ba-
sic models variables plus the cardiovascular comorbidity
score (the detailed models will be provided to interested
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Fig. 1. Explained mortality variance (%). Besides C-reactive protein-
brain natriuretic peptide (CRP-BNP) and CRP-asymmetric dimethyl
arginine (ADMA) scores variables included in multivariate analyses of
various complexity are age, gender, smoking, diabetes, albumin, treat-
ment modality and comorbidity score for all-cause death and age, gen-
der, smoking, diabetes, and comorbidity score for cardiovascular death.
The statistical models are described in the Results section. A table with
the detailed list of causes of death can be obtained from the authors.
readers on request). In these analyses BNP, ADMA,
and CRP added significant predictive value (all P ≤
0.01) to all-cause (BNP +5.7%; ADMA +5.6%; and
CRP +3.8%) and cardiovascular mortality (BNP +4.9%;
ADMA +3.3%; and CRP +5.4%) models and the ex-
planatory gain for these outcomes attributable to these
biomarkers was of similar degree. Accordingly, the rel-
ative risks associated with high BNP, ADMA, and CRP
(expressed as tertiles to allow direct comparison) were
largely overlapping (Fig. 2). The survival curves by ter-
tiles of BNP, ADMA, and CRP for all-cause and cardio-
vascular mortality are reported in Figure 3.
Combined prognostic power of BNP, ADMA, and CRP
The combined prognostic value of plasma BNP,
ADMA, and CRP was evaluated by the “biomarker
score” (i.e., the sum of these variables categorized in
Table 2. Cox regression analysis for all-cause and cardiovascular
mortality, including covariates of the basic models and the
comorbidity score
Units of increase HR and 95% CI P value
All-cause mortality
Age 1 year 1.04 (1.02–1.06) <0.001
Male gender 1.51 (0.89–2.55) 0.12
Smoking 1.22 (0.73–2.02) 0.45
Diabetes 1.61 (1.00–2.60) 0.05
Albumin 1 g/L 0.95 (0.91–0.99) 0.02
Treatment modality 0 hemodialysis; 0.91 (0.52–1.61) 0.75
1 CAPD
Comorbidity score 0 1a
1 1.62 (0.97–2.72) 0.06
2–3 2.44 (1.44–2.14) 0.001
>3 4.72 (2.09–10.65) <0.001
Cardiovascular mortality
Age 1 year 1.04 (1.02–1.06) <0.001
Male gender 2.19 (1.11–4.31) 0.02
Smoking 1.15 (0.62–2.12) 0.66
Diabetes 1.40 (0.76–2.60) 0.28
Comorbidity score 0 1a
1 1.81 (0.89–3.68) 0.10
2–3 3.36 (1.72–6.58) <0.001
>3 8.59 (3.41–21.61) <0.001
CAPD is continuous ambulatory peritoneal dialysis. Factors which were not in-
troduced into the two Cox models were those with P > 0.10 at univariate analysis.
The list of these variables may be deduced from the description of the multivari-
able strategy adopted in this study (see Methods section).
aReference group.
terms of tertiles). For the sake of parsimony, we first eval-
uated a biomarker score based on two biomarkers (CRP
and BNP, CRP and ADMA, and ADMA and BNP).
When the score derived from CRP and BNP was added
to models incorporating the comorbidity score, the ex-
plained all-cause mortality variance rose from 45.4% to
55.3% (+9.9%) and the explained cardiovascular mor-
tality variance from 36.4% to 46.9% (+10.5%) (Fig. 1).
Such gain in power was similar to that achieved by the
CRP and ADMA combination (all-cause death +9.0%
and cardiovascular death +8.4%) (Fig. 1). The BNP and
ADMA combination was less informative than the other
two combinations (all-cause death +7.7% and cardiovas-
cular death +5.6%). The explanatory gain derived by the
simultaneous use of the three biomarkers (all-cause death
+11.6% and cardiovascular death +10.5%) was almost
identical to that obtained by the combination of just two
biomarkers. Of note, both with the CRP-BNP and the
CRP-ADMA combinations the risk increased in paral-
lel with the plasma levels of corresponding biomarkers
(biomarker score) (Fig. 4).
DISCUSSION
This study shows that in ESRD patients the combined
use of biomarkers of inflammation, endothelial dysfunc-
tion, and myocardiopathy increases by about one fifth
the explanatory power of all-cause and cardiovascular
mortality models based on traditional risk factors, serum
albumin, and comorbidities.
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Fig. 2. HR and 95% CI for all-cause
and cardiovascular mortality associated with
brain natriuretic peptide (BNP), asymmetric
dimethyl arginine (ADMA), and C-reactive
protein (CRP) (third vs. first tertile). Data
were appropriately adjusted for covariates in-
cluded in the corresponding basic models of
all-cause and cardiovascular death as well as
for the comorbidity score. The categorization
into tertiles was chosen because it produced
a better data fitting than that into quartiles or
quintiles. BNP in I tertile <14.3 pmol/L, II ter-
tile ≥14.3 <36.1 pmol/L, and III tertile >36.1
pmol/L; ADMA I tertile <2.20 lmol/L, II ter-
tile ≥2.20 <3.87 lmol/L, and III tertile >3.87
lmol/L; and CRP I tertile <3.4 mg/L, II tertile
≥3.4 <13.0 mg/L, and III tertile >13.0 mg/L.
We divided the study population in tertiles be-
cause this categorization gave the best fitting
with observed survival data.
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Fig. 3. Cox survival curves by tertiles of brain natriuretic peptide (BNP), asymmetric dimethyl arginine (ADMA), and C-reactive protein (CRP)
for all0cause and cardiovascular mortality. Data were appropriately adjusted for covariates included in the corresponding basic models as well as
for the comorbidity score.
The alarming rate of cardiovascular events in dialy-
sis patients demands accurate risk profiling to identify
individuals at greater risk and therefore needing inten-
sive surveillance and treatment. Atherosclerosis is a risk
factor both for renal disease and cardiovascular compli-
cations and undoubtedly the burden of cardiovascular
events antedating ESRD in part explains why these pa-
tients are so predisposed to cardiovascular complications
and death. As is commonly observed in American and
in European dialysis populations, our cohort was rela-
tively old and about one half of patients had evidence
of cardiac ischemia, cerebrovascular or peripheral dis-
ease. It is well-known that background cardiovascular
events constitute a strong predictor for future events, a
notion further again confirmed by our prospective obser-
vations. In keeping with previous large-scale analyses in
the ESRD population [18, 19] we found that age, gender,
diabetes, smoking, and serum albumin were independent
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Fig. 4. HR and 95% CI for all-cause and cardiovascular mortality associated to the C-reactive protein-brain natriuretic peptide (CRP-BNP) and to
CRP-asymmetric dimethyl arginine (ADMA) biomarker scores. Biomarker scores were calculated on individual basis by summing up the variables
(CRP and BNP and CRP and ADMA) expressed as tertiles. Data were appropriately adjusted for covariates included in the corresponding basic
model of all-cause and cardiovascular death as well as for the comorbidity score.
risk factors for death in the CREED cohort. However, the
combined effect of these risk factors and of background
cardiovascular complications explained only about 45%
of mortality variance in these patients. Framingham risk
factors account for more than the 80% of coronary events
in individuals without cardiovascular events at baseline
in the general population [20] but it is well documented
that the explanatory power of traditional risk factors for
cardiovascular events is much less in ESRD patients than
in their age peers without renal diseases [21, 22]. The lim-
ited prognostic value of traditional risk factors in ESRD
implies that attention should be focused also on other
risk factors both to improve prediction of future events
(i.e., for prognosis) and to identify modifiable risk factors
which can be targeted by specific treatments (i.e., for pre-
vention). In this regard CRP has now emerged as a solid,
independent predictor of death risk in the dialysis pop-
ulation [3–5]. Although there is still no evidence either
in the general population or in the dialysis population
that lowering CRP will necessarily lower cardiovascular
risk, this biomarker conveys important prognostic infor-
mation beyond traditional risk factors and background
cardiovascular events [3, 5]. BNP is a sensitive guide to
the presence of LVH and left ventricular dysfunction in
asymptomatic subjects [23], and such characteristics have
been specifically confirmed in the ESRD population [6].
ADMA mediates the effects of many risk factors and
risk markers on the NOS pathway and it is currently con-
sidered an important biomarker reflecting the summa-
tive effect of various risk factors on endothelial function
[24], a hypothesis specifically supported by the observa-
tion that this substance is independently associated to
mortality and cardiovascular events in the dialysis popu-
lation [9]. We focused the attention on these biomarkers
because they reflect a wide range of pathologic processes
encompassing atherosclerosis and the risk for thrombo-
sis. In fact their combined use increased the explanatory
power for mortality and cardiovascular events of mul-
tivariate models based on standard risk factors and on
comorbidities by about one fifth. Such an explanatory
gain is important because the incidence of de novo car-
diovascular disease in patients with ESRD is much higher
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than predicted on the basis of traditional risk factors [21,
22]. In this regard it is important noting that the com-
bination of two biomarkers, CRP and BNP or CRP and
ADMA, was almost as informative as the combination
of three biomarkers. This finding has biologic plausibil-
ity because, as previously noted, these biomarkers in part
reflect overlapping pathologic processes [8, 25–28]. It is
worth noting that the two biomarkers which formed the
best prognostic combination, BNP and CRP, both possess
the major characteristics required for a marker to be rec-
ommended for a wide use in clinical practice, namely, it
should provide independent information in risk or prog-
nosis beyond established risk factors and that it should be
easy to measure and in a cost-effective manner. ADMA
is a strong predictor of death and cardiovascular events
but the measurement of plasma levels of this substance
are still poorly standardized and performed only in few
laboratories. The ideal biomarker should also have the
characteristic that a reduction in its levels leads to re-
duced vascular risk but this is not a critical issue for risk
prediction. Recently completed [29] and ongoing trials
will provide specific answers to the hypothesis that CRP
and BNP may be a guide to treatment in ESRD patients. If
positive, these trials will constitute a definitive argument
for the widespread use of these biomarkers in the dial-
ysis population. In the specific case of ESRD, CRP and
BNP may also have other practical implications because
the measurement of circulating levels of these substances
may be useful also for comparing the cardiovascular bur-
den of diverse dialysis populations. Indeed comorbidities
may not accurately reflect the actual severity of underly-
ing organ damage. On the other hand, even comparisons
based on fatal events may be imperfect because deter-
mination of cause of death using death notifications is
notoriously inaccurate [30] and because a poor correla-
tion exists between type of cardiac death as determined
by clinicians and as adjudicated by expert panels [31].
Because CRP and BNP biologically reflect the burden of
atherosclerosis and myocardial disease, their systematic
use may allow more objective comparison of different
dialysis units, an exercise which may result much useful
both for research purposes as well as for benchmarking.
CONCLUSION
For steady-state patients with ESRD without inter-
current inflammatory processes or acute coronary syn-
dromes and without heart failure, levels of CRP and BNP
independently identify patients at risk of death and the
combination of the two biomarkers identify patients at
particularly high risk. In the aggregate, these findings
identify a potential role for these biomarkers to be incor-
porated into diagnostic and therapeutic strategies aimed
at detection and treatment of atherosclerotic complica-
tions and heart failure prevention strategies.
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